---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-111285"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:21:04.120387+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q3 revenue $20.7M (+9% YoY); upsizes credit facility to $70M with Perceptive

## Summary
- Q3 revenue $20.7M (+9% YoY); net loss $8.6M vs $10.4M year ago; operating loss $7.6M.
- Full-year 2025 revenue guidance revised to at least 16% growth over 2024.
- Closed $70M credit facility from Perceptive Advisors: $60M initial draw, $10M accordion; interest rate 7.85%+greater of Term SOFR or 4.25%, interest-only to Nov 2030.
- Appointed Betty Jo Rocchio and Bill Plovanic to the Board of Directors.

## SEC filing metadata
- accession: 0001104659-25-111285
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465925111285/0001104659-25-111285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465925111285/tm2531116d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-111285
- JSON: https://secwatch.observer/filing/0001104659-25-111285.json
- Plain text: https://secwatch.observer/filing/0001104659-25-111285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.